tagraxofusp-erzs
View Patient InformationA recombinant protein consisting of human interleukin 3 (IL3) fused to the first 388 amino acids of diphtheria toxin [DT(388)] (DT388IL3) with potential antineoplastic activity. Upon intravenous administration of tagraxofusp-erzs, the IL3 moiety binds to IL3 receptors on cells expressing the receptor. Subsequently, the DT(388) toxin moiety, which contains both translocation and catalytic domains, is transported across the cell membrane via endocytosis. Within the cytosol, the catalytic domain of the toxin both catalyzes the ADP-ribosylation of, and inactivates, translation elongation factor 2 (EF-2), which results in the inhibition of translation during protein synthesis. IL3 may be overexpressed by a variety of cancers, including blastic plasmacytoid dendritic cell neoplasm and acute myeloid leukemia (AML).
| Synonym: | diphtheria toxin(388)-interleukin-3 fusion protein DT(388)-IL3 fusion protein DT(388)IL3 fusion protein SL-401 IL3R-targeting fusion protein SL-401 tagraxofusp tagraxofusp ERZS |
|---|---|
| US brand name: | Elzonris |
| Code name: | SL-401 |
| Chemical structure: | S)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol |